Federation Des Caisses Desjardins Du Quebec Catalyst Pharmaceuticals, Inc. Transaction History

Federation Des Caisses Desjardins Du Quebec

$18.9 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 14, 2024	SELL	$11.78 - $17.29 $494 - $726	-42 Closed	0 $0
Q3 2023 Aug 14, 2024	SELL	$11.69 - $15.02 $1,730 - $2,222	-148 Reduced 77.89%	42 $491,000
Q2 2023 Aug 14, 2024	BUY	$11.5 - $18.08 $2,185 - $3,435	190 New	190 $2.55 Million

Others Institutions Holding CPRX

# of Institutions

326

Shares Held

94.6M

Call Options Held

19.1K

Put Options Held

51.1K

Black Rock Inc. New York, NY

18.7M
Shares

$385 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

8.04M
Shares

$166 Million
0.0% of portfolio
Deerfield Management Company, L.P. (Series C) New York, NY

6.23M
Shares

$128 Million
2.3% of portfolio
State Street Corp Boston, MA

5.69M
Shares

$117 Million
0.0% of portfolio
Dimensional Fund Advisors LP Austin, TX

3.02M
Shares

$62.2 Million
0.01% of portfolio

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.12B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Account